(-0.75%) 5 069.25 points
(-0.59%) 38 450 points
(-1.07%) 17 475 points
(0.13%) $82.92
(1.03%) $1.670
(0.14%) $2 341.60
(0.47%) $27.48
(-0.28%) $913.20
(-0.18%) $0.933
(-0.35%) $10.94
(-0.38%) $0.799
(-0.30%) $92.05
-2.66% ¥ 7 148.00
Live Chart Being Loaded With Signals
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan...
Stats | |
---|---|
Today's Volume | 647 900 |
Average Volume | 1.07M |
Market Cap | 2 097.18B |
EPS | ¥0 ( 2024-01-30 ) |
Next earnings date | ( ¥135.09 ) 2024-05-08 |
Last Dividend | ¥75.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 13.50 |
ATR14 | ¥2.36 (0.03%) |
Volume Correlation
Shionogi & Co., Ltd. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Shionogi & Co., Ltd. Correlation - Currency/Commodity
Shionogi & Co., Ltd. Financials
Annual | 2022 |
Revenue: | ¥426.68B |
Gross Profit: | ¥364.44B (85.41 %) |
EPS: | ¥621.31 |
Q3 | 2023 |
Revenue: | ¥106.28B |
Gross Profit: | ¥91.76B (86.34 %) |
EPS: | ¥126.93 |
Q2 | 2023 |
Revenue: | ¥121.23B |
Gross Profit: | ¥106.47B (87.82 %) |
EPS: | ¥164.08 |
Q1 | 2023 |
Revenue: | ¥109.31B |
Gross Profit: | ¥96.19B (88.00 %) |
EPS: | ¥144.62 |
Financial Reports:
No articles found.
Shionogi & Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥60.00 (N/A) |
¥0 (N/A) |
¥75.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥4.25 | 2000-03-28 |
Last Dividend | ¥75.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 48 | -- |
Total Paid Out | ¥1 157.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.44 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 7.37 | |
Div. Directional Score | 9.88 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9366.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8237.T | Ex Dividend Junior | 2024-02-28 | Annually | 0 | 0.00% | |
7608.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
6806.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6146.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4886.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4061.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3282.T | Ex Dividend Junior | 2024-01-30 | Semi-Annually | 0 | 0.00% | |
2325.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
9946.T | Ex Dividend Junior | 2024-02-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.363 | 1.500 | 2.73 | 4.10 | [0 - 0.5] |
returnOnAssetsTTM | 0.114 | 1.200 | 6.21 | 7.46 | [0 - 0.3] |
returnOnEquityTTM | 0.132 | 1.500 | 9.64 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.288 | -1.000 | 7.12 | -7.12 | [0 - 1] |
currentRatioTTM | 6.57 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.74 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.47 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00724 | -1.500 | 9.88 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 14.19 | 1.000 | 5.85 | 5.85 | [3 - 30] |
operatingCashFlowPerShareTTM | 445.43 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 362.35 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00826 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.859 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.332 | 1.000 | 5.35 | 5.35 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 13.06 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.313 | 0.800 | -1.249 | -0.999 | [0.5 - 2] |
Total Score | 12.39 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.40 | 1.000 | 8.75 | 0 | [1 - 100] |
returnOnEquityTTM | 0.132 | 2.50 | 9.77 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 362.35 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.09 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 445.43 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.288 | 1.500 | 7.12 | -7.12 | [0 - 1] |
pegRatioTTM | 3.56 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.302 | 1.000 | 4.94 | 0 | [0.1 - 0.5] |
Total Score | 7.37 |
Shionogi & Co., Ltd.
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators